BRAF and neoplasm: In contrast, patients with LEATs demonstrating astrocytic differentiation, BRAF mutation as well as activation of MAPK/FGFR/EGFR oncogene pathways are at higher risk of tumor recurrence and malignant progression (Fig. 3).